Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/f6f0f4bb-36d0-4f62-9ce6-3448de0bbb97/
RIGL
Rigel Pharmaceuticals IncSnapshot 2026-06-07 · 0.0w · Fresh
Strategy Eligibility
7 of 23 passing
★
OS Composite
OS 0.980
↗
Trending Value
✗
◆
Quality × Value
QV 0.930
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
P/E 1.6
◇
VC2 Cheapest
✗
📐
EBITDA/EV
21.5%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
ROE 91%
📈
Consistent Earners
✗
🌱
GARP
Rev +48%
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
Val 94th
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
94.0%ile
P/E
1.6×
P/S
2.0×
P/B
1.5×
E/P
0.6182
FCF Yield
0.130
EBITDA/EV
0.215
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
9.00000000
/100 — 1=cheapest
VC2 (Trending Value)
15.00000000
/100
VC3 (Buyback)
15.00000000
/100
P/E of 1.6x places this firmly in deep value territory. FCF yield of 13.0% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
92.0%ile
ROE
0.911
ROA
0.722
Net Margin
1.215
Op Margin
0.430
GPA
0.555
D/E
0.26
Current
2.62
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.476
Earn Growth
8.797
Stability
1.792
lower=better
Accruals
0.565
lower=better
5yr Consist
No
ROE of 91% is exceptional. Conservative balance sheet with D/E of 0.26. Accruals ratio of 0.565 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
76.0%ile
6M Return
-38.8%
12M Return
39.3%
12-1 Mom
21.2%
Risk-Adj
0.28
Vol 252d
75.4%
Vol 60d
132.0%
↑ Expanding
Max DD 12M
-48.9%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 21% is very strong — a clear uptrend. Near-term vol (132%) is expanding vs long-term (75%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.98
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare
· 500 peers
Sector Value %ile
98.4%
Sector Quality %ile
92.6%
P/E z-score
-0.43
P/B z-score
-0.29
Sector Avg OS
63.2%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (94th) and quality (92th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Trending Value Signal
Cheap (94th value) with strong momentum (76th). The market is starting to recognise the value.
Growth at Reasonable Price
Revenue growing 48% with P/E of 2×. Growth isn't fully priced in.
Earnings Quality Concern
ROE looks strong (91%) but high accruals (0.565) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (132%) significantly exceeds 252-day (75%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
A
83.8% avg (7 factors)
Quality
A
84.8% avg (8 factors)
Momentum
D
42.6% avg (4 factors)
Risk
F
0.0% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
| Factor | Current | Streak | Trend | Spark |
|---|---|---|---|---|
| OS Composite | 0.980 | —1 | — | |
| Value %ile | 0.940 | —1 | — | |
| Quality %ile | 0.920 | —1 | — | |
| Momentum %ile | 0.760 | —1 | — | |
| F-Score | 6.000 | —0 | — | |
| Confidence | 1.000 | —1 | — | |
| Volatility | 0.754 | —1 | — |
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
1.62
Earnings Yield (E/P)
0.6182
Price / Sales
1.97
Price / Book
1.47
Price / Cash Flow
7.43
FCF Yield
13.0%
EBITDA / EV
21.5%
Sales Yield (1/P·S)
0.4912
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
91.1%
Return on Assets
72.2%
Net Margin
121.5%
Operating Margin
43.0%
Gross Profit / Assets
Novy-Marx GPA
55.5%
Debt / Equity
0.26
Current Ratio
2.62
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.565
MomentumPrice trend strength over different horizons
6M Return
-38.8%
12M Return
39.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
21.2%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.28
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
47.6%
Earnings Growth (YoY)
879.7%
Earnings Stability (CV)
Lower = more stable
1.792
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
9
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
15
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
15
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity